These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30224159)

  • 41. Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease?
    MacDonald HJ; Byblow WD
    J Mot Behav; 2015; 47(1):29-45. PubMed ID: 25575221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impulse control disorders in Parkinson's disease: crossroads between neurology, psychiatry and neuroscience.
    Bugalho P; Oliveira-Maia AJ
    Behav Neurol; 2013 Jan; 27(4):547-57. PubMed ID: 23242359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson's disease.
    Ramdave S; Dawson A; Carter A; Dissanayaka NNW
    Brain Imaging Behav; 2020 Dec; 14(6):2785-2798. PubMed ID: 30707344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease.
    Liu B; Luo W; Mo Y; Wei C; Tao R; Han M
    Neurosci Lett; 2019 Aug; 707():134313. PubMed ID: 31167116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impulse control disorders in Parkinson's disease: A systematic review on risk factors and pathophysiology.
    Latella D; Maggio MG; Maresca G; Saporoso AF; Le Cause M; Manuli A; Milardi D; Bramanti P; De Luca R; Calabrò RS
    J Neurol Sci; 2019 Mar; 398():101-106. PubMed ID: 30690412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder.
    Fantini ML; Macedo L; Zibetti M; Sarchioto M; Vidal T; Pereira B; Marques A; Debilly B; Derost P; Ulla M; Vitello N; Cicolin A; Lopiano L; Durif F
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):174-9. PubMed ID: 25006210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.
    Taylor J; Anderson WS; Brandt J; Mari Z; Pontone GM
    Am J Geriatr Psychiatry; 2016 Dec; 24(12):1171-1180. PubMed ID: 27746069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impulse control disorders in Parkinson's disease.
    Vilas D; Pont-Sunyer C; Tolosa E
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S80-4. PubMed ID: 22166463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Parkinson disease: impulsive choice-Parkinson disease and dopaminergic therapy.
    Voon V; Dalley JW
    Nat Rev Neurol; 2011 Sep; 7(10):541-2. PubMed ID: 21912409
    [No Abstract]   [Full Text] [Related]  

  • 50. Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders.
    Ceravolo R; Frosini D; Rossi C; Bonuccelli U
    J Neurol; 2010 Nov; 257(Suppl 2):S276-83. PubMed ID: 21080189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perceptual decision-making in patients with Parkinson's disease.
    Djamshidian A; O'Sullivan SS; Lawrence AD; Foltynie T; Aviles-Olmos I; Magdalinou N; Tomassini A; Warner TT; Lees AJ; Averbeck BB
    J Psychopharmacol; 2014 Dec; 28(12):1149-54. PubMed ID: 25237123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review.
    Nakum S; Cavanna AE
    Parkinsonism Relat Disord; 2016 Apr; 25():10-6. PubMed ID: 26923525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
    Debove I; Paschen S; Amstutz D; Cardoso F; Corvol JC; Fung VSC; Lang AE; Martinez Martin P; Rodríguez-Oroz MC; Weintraub D; Krack P; Deuschl G;
    Mov Disord; 2024 Feb; 39(2):235-248. PubMed ID: 38234035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.
    Schaeffer E; Berg D
    CNS Drugs; 2017 Jul; 31(7):551-570. PubMed ID: 28643183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease.
    Kraemmer J; Smith K; Weintraub D; Guillemot V; Nalls MA; Cormier-Dequaire F; Moszer I; Brice A; Singleton AB; Corvol JC
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1106-11. PubMed ID: 27076492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prevalence and clinical characteristics of punding in Parkinson's disease.
    Spencer AH; Rickards H; Fasano A; Cavanna AE
    Mov Disord; 2011 Mar; 26(4):578-86. PubMed ID: 21648123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease.
    Bellosta Diago E; Lopez Del Val LJ; Santos Lasaosa S; López Garcia E; Viloria Alebesque A
    Neurologia; 2017 Oct; 32(8):494-499. PubMed ID: 27087472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study.
    Vela L; Martínez Castrillo JC; García Ruiz P; Gasca-Salas C; Macías Macías Y; Pérez Fernández E; Ybot I; Lopez Valdés E; Kurtis MM; Posada Rodriguez IJ; Mata M; Ruiz Huete C; Eimil M; Borrue C; Del Val J; López-Manzanares L; Rojo Sebastian A; Marasescu R
    J Neurol Sci; 2016 Sep; 368():150-4. PubMed ID: 27538621
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome.
    Cilia R; Siri C; Canesi M; Zecchinelli AL; De Gaspari D; Natuzzi F; Tesei S; Meucci N; Mariani CB; Sacilotto G; Zini M; Ruffmann C; Pezzoli G
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):311-8. PubMed ID: 23591553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention.
    Antonini A; Cilia R
    Drug Saf; 2009; 32(6):475-88. PubMed ID: 19459715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.